Montelukast API Market: Highlights
The asthma segment is expected to lead the market and register a substantial CAGR to reach USD 700,730.7 thousand by the end of 2023 owing to the rising prevalence of asthma. Montelukast API is much in demand across the globe for the treatment of asthma. However, the allergic rhinitis segment is projected to exhibit the highest CAGR of 3.11% from 2018 to 2023. The rising rate of allergic rhinitis cases is driving the growth of the segment.
North America accounted for the largest market share of 39.25% in 2017, and the regional market is projected to register a CAGR of 3.12% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.10% during the forecast period from 2018 to 2023.
Get Free Sample Report at https://www.marketresearchfuture.com/sample_request/7886
Market Players:
Market Research Future (MRFR) recognizes Merck Sharp & Dohme Corp (US), Dr. Reddy’s Laboratories Ltd (India), Morepen Laboratories Ltd (India), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (Israel), Hikma Pharmaceuticals PLC (UK), Glenmark (India), Sandoz International GmbH (Germany), Vintage Pharmaceuticals Inc (US), Hetero (India) and Aurobindo Pharma (India) as the key players in the global montelukast API market.
Segment Analysis:
The global montelukast API market has been segmented on the basis of applications, and region. On the basis of the applications, the market has been divided into asthma, allergic rhinitis, bronchospasm, urticarial and others. The asthma segment held the majority market share in 2017. Allergic rhinitis segment is expected to be the fastest growing, followed by the asthma segment. Rising prevalence of allergic rhinitis is driving the growth of the segment.
Regional Analysis:
North America accounted for the largest market share of 39.25% in 2017, and the regional market is projected to register a CAGR of 3.12% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.10% during the forecast period from 2018 to 2023.
The European market is estimated to exceed USD 396,258 thousand by 2023. Increasing incidence of asthma, COPD, and allergies are driving the growth of the Montelukast API market in the region. The UK is the major contributor to the growth of the regional market, followed by France.
Browse Complete 85 Pages Premium Research Report Enabled with 76 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/montelukast-api-market-7886
Major Table of Content by “Montelukast API Market Research Report – Global Forecast till 2023”
1 Executive Summary
1.1 Market Attractiveness Analysis
1.1.1 Global Montelukast API Market, By Application
1.1.2 Global Montelukast API Market, By Region
2 Market Introduction
2.1 Definition
2.2 Scope of The Study
2.3 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
About Us:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/big-data-as-a-service-market-1209